Nextcure Stock Buy Hold or Sell Recommendation
| NXTC Stock | USD 1.19 0.10 7.75% |
Given the investment horizon of 90 days and your highly speculative risk level, our recommendation regarding NextCure is 'Strong Sell'. Macroaxis provides NextCure buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding NextCure positions.
Check out NextCure Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide. In addition, we conduct extensive research on individual companies such as NextCure and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards NextCure. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
NextCure |
Execute NextCure Buy or Sell Advice
The NextCure recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on NextCure. Macroaxis does not own or have any residual interests in NextCure or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute NextCure's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
NextCure Trading Alerts and Improvement Suggestions
| NextCure generated a negative expected return over the last 90 days | |
| NextCure may become a speculative penny stock | |
| NextCure has high historical volatility and very poor performance | |
| NextCure has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (62.72 M) with loss before overhead, payroll, taxes, and interest of (54.2 M). | |
| NextCure currently holds about 185.49 M in cash with (52.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| NextCure has a frail financial position based on the latest SEC disclosures | |
| Roughly 58.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Feigal Ellen of 14250 shares of NextCure subject to Rule 16b-3 |
NextCure Returns Distribution Density
The distribution of NextCure's historical returns is an attempt to chart the uncertainty of NextCure's future price movements. The chart of the probability distribution of NextCure daily returns describes the distribution of returns around its average expected value. We use NextCure price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of NextCure returns is essential to provide solid investment advice for NextCure.
| Mean Return | -0.36 | Value At Risk | -6.37 | Potential Upside | 5.22 | Standard Deviation | 3.61 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of NextCure historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
NextCure Stock Institutional Investors
| Shares | Acuitas Investments, Llc | 2024-09-30 | 342.6 K | Federated Hermes Inc | 2024-09-30 | 321.5 K | Bml Capital Management Llc | 2024-09-30 | 276.5 K | Cardiff Park Advisors, Llc | 2024-06-30 | 262 K | Geode Capital Management, Llc | 2024-09-30 | 223.7 K | Macquarie Group Ltd | 2024-06-30 | 150 K | Sio Capital Management, Llc | 2024-09-30 | 130 K | Adar1 Capital Management Llc | 2024-09-30 | 120 K | Hudson Bay Capital Management Lp | 2024-09-30 | 107.7 K | Logos Global Management Lp | 2024-06-30 | 5 M | Sofinnova Ventures | 2024-06-30 | 2.7 M |
NextCure Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (303.9M) | 50.7M | 39.0M | 68.0M | 39.6M | 41.6M | |
| Change In Cash | (96.5M) | (2.8M) | (23.9M) | 14.3M | (13.5M) | (12.9M) | |
| Net Borrowings | (400K) | 4.5M | (1.5M) | (3.5M) | (3.1M) | (3.0M) | |
| Free Cash Flow | (39.0M) | (52.1M) | (59.6M) | (56.0M) | (53.8M) | (56.5M) | |
| Depreciation | 2.7M | 3.4M | 7.2M | 4.1M | 3.7M | 3.7M | |
| Capital Expenditures | 3.4M | 7.1M | 2.4M | 2.1M | 820K | 779K | |
| Net Income | (33.7M) | (36.6M) | (69.4M) | (74.7M) | (62.7M) | (65.9M) | |
| End Period Cash Flow | 39.1M | 36.3M | 12.4M | 26.6M | 13.1M | 12.4M | |
| Change To Netincome | 1.9M | 7.9M | 10.3M | 9.6M | 11.0M | 11.6M | |
| Other Non Cash Items | 7.3M | 12.7M | 23.7M | 3.5M | (183K) | (192.2K) |
NextCure Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to NextCure or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that NextCure's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a NextCure stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.35 | |
β | Beta against Dow Jones | -0.18 | |
σ | Overall volatility | 3.65 | |
Ir | Information ratio | -0.14 |
NextCure Volatility Alert
NextCure exhibits very low volatility with skewness of 0.67 and kurtosis of 2.71. NextCure is a potential penny stock. Although NextCure may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in NextCure. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on NextCure instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.NextCure Fundamentals Vs Peers
Comparing NextCure's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze NextCure's direct or indirect competition across all of the common fundamentals between NextCure and the related equities. This way, we can detect undervalued stocks with similar characteristics as NextCure or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of NextCure's fundamental indicators could also be used in its relative valuation, which is a method of valuing NextCure by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare NextCure to competition |
| Fundamentals | NextCure | Peer Average |
| Return On Equity | -0.55 | -0.31 |
| Return On Asset | -0.31 | -0.14 |
| Current Valuation | (36.59 M) | 16.62 B |
| Shares Outstanding | 28.01 M | 571.82 M |
| Shares Owned By Insiders | 8.85 % | 10.09 % |
| Shares Owned By Institutions | 57.50 % | 39.21 % |
| Number Of Shares Shorted | 66.12 K | 4.71 M |
| Price To Earning | (25.44) X | 28.72 X |
| Price To Book | 0.44 X | 9.51 X |
| Price To Sales | 9.52 X | 11.42 X |
| Gross Profit | (54.2 M) | 27.38 B |
| EBITDA | (59.04 M) | 3.9 B |
| Net Income | (62.72 M) | 570.98 M |
| Cash And Equivalents | 185.49 M | 2.7 B |
| Cash Per Share | 6.68 X | 5.01 X |
| Total Debt | 6.61 M | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 33.87 X | 2.16 X |
| Book Value Per Share | 4.10 X | 1.93 K |
| Cash Flow From Operations | (52.97 M) | 971.22 M |
| Short Ratio | 1.89 X | 4.00 X |
| Earnings Per Share | (2.10) X | 3.12 X |
| Price To Earnings To Growth | 0.03 X | 4.89 X |
| Target Price | 3.33 | |
| Number Of Employees | 82 | 18.84 K |
| Beta | 0.79 | -0.15 |
| Market Capitalization | 33.33 M | 19.03 B |
| Total Asset | 128.04 M | 29.47 B |
| Retained Earnings | (324.48 M) | 9.33 B |
| Working Capital | 105.84 M | 1.48 B |
| Current Asset | 46.99 M | 9.34 B |
| Current Liabilities | 5.53 M | 7.9 B |
| Net Asset | 128.04 M |
Note: Acquisition by Feigal Ellen of 14250 shares of NextCure subject to Rule 16b-3 [view details]
NextCure Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as NextCure . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About NextCure Buy or Sell Advice
When is the right time to buy or sell NextCure? Buying financial instruments such as NextCure Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having NextCure in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Steel Works Etc Thematic Idea Now
Steel Works Etc
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Steel Works Etc theme has 54 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Steel Works Etc Theme or any other thematic opportunities.
| View All Next | Launch |
Check out NextCure Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NextCure. If investors know NextCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NextCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.10) | Quarterly Revenue Growth (1.00) | Return On Assets (0.31) | Return On Equity (0.55) |
The market value of NextCure is measured differently than its book value, which is the value of NextCure that is recorded on the company's balance sheet. Investors also form their own opinion of NextCure's value that differs from its market value or its book value, called intrinsic value, which is NextCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NextCure's market value can be influenced by many factors that don't directly affect NextCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NextCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if NextCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NextCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.